Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

Accessibility StatementSkip Navigation PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 6, 2025 /PRNewswire/ --Â At ObesityWeekÂ (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, including hypertension and systemic inflammation. The results from the post hoc analysis of REDEFINE ...